Crispr Therapeutics AG vs InMode Ltd — how do they compare? Crispr Therapeutics AG trades at $53.82 (market cap $5.23B), while InMode Ltd trades at $15.23 (market cap $872.08M). The key difference: Crispr Therapeutics AG is far larger — about 6× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | INMD | |
|---|---|---|
Market Cap | $5.23B | $872.08M |
Sector | Health | Technology |
52-Week High | $76.78 | $16.62 |
52-Week Low | $44.34 | $12.76 |
Enterprise Value | $3.65B | $375.42M |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
InMode (INMD) trades at $15.17, down slightly by 0.13% today, with neutral technical signals and mixed earnings performance. The company maintains strong profitability with 76.52% gross margins and 20.69% net income margins, though Q1 2026 earnings missed expectations. Recent news highlights acquisition interest from Steel Partners at $16.75 per share and ongoing shareholder activism, creating both opportunity and uncertainty around corporate governance and valuation.
The stock presents a value opportunity with low P/E (12.52) and EV/EBITDA (5.37) multiples, but faces risks from earnings volatility, shareholder disputes, and potential undervaluation concerns. Analyst consensus leans neutral with 45% buy ratings, while technical indicators suggest range-bound trading near key support at $15. Investment appeal hinges on resolution of acquisition talks and sustained execution amid competitive pressures.
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →